NCT05605509 2026-02-06
RP-6306 in Patients With Advanced Cancer
Canadian Cancer Trials Group
Phase 2 Completed
Canadian Cancer Trials Group
Bristol-Myers Squibb
Duke University
Bristol-Myers Squibb
Bristol-Myers Squibb
Agenus Inc.
Prescient Therapeutics, Ltd.
ElmediX
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Bristol-Myers Squibb